네바다의 과체중 임상 시험
과체중 관련 연구 24개가 네바다 내 여러 지역에서 참여자를 모집하고 있습니다.
네바다의 도시
공식 연구 텍스트(영어)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Vector Clinical Trials /ID# 282265, Las Vegas
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT07752979A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- M3 Wake Research - Las Vegas Cimarron, Las Vegas
- Renascor Clinical Research, Reno
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07794579AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Palm Research Center Inc., Las Vegas
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07720271A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Las Vegas
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07776509A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Las Vegas Medical Research, Las Vegas
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07589608A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Palm Research Center Tenaya, Las Vegas
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07369011A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- AMR Clinical, Las Vegas
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07321886Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Excel Clinical Research, Las Vegas
- Vector Clinical Trials, Las Vegas
피험자 모집 중3상
45세 ~ 99세 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07037433A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Las Vegas
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Las Vegas
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT07743450A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Las Vegas
피험자 모집 중3상건강한 지원자 환영
18세 ~ 79세 · 모든 성별 · 2026. 9. 11. 업데이트됨 · NCT07654374Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- Jubilee Clinical Research, Inc., Las Vegas
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT07770841A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- Vector Clinical Trials, Las Vegas
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT07215559A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Las Vegas Medical Research, Las Vegas
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Skin Cancer and Dermatology Institute - Reno, Reno
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT06857942Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Las Vegas
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Palm Research Center Inc, Las Vegas
피험자 모집 중3상
18세 ~ 99세 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT07684144Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Las Vegas
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Palm Research Center Inc, Las Vegas
- Vector Clinical Trials, Las Vegas
피험자 모집 중3상
18세 ~ 99세 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT07684235Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.
- University of Nevada, Las Vegas, Las Vegas
피험자 모집 중건강한 지원자 환영
21세 ~ 74세 · 모든 성별 · 2026. 8. 27. 업데이트됨 · NCT07566325Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Excel Clinical Research, Las Vegas
피험자 모집 중3상
18세 ~ 99세 · 모든 성별 · 2026. 8. 27. 업데이트됨 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Las Vegas
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT07784725Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Las Vegas
피험자 모집 중3상
18세 ~ 79세 · 모든 성별 · 2026. 8. 10. 업데이트됨 · NCT07654361A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
- Corxel Investigational site, Las Vegas
피험자 모집 중1상
18세 ~ 55세 · 여성 · 2026. 6. 17. 업데이트됨 · NCT07652047ClinicalTrials.gov 출처, 2026. 9. 30. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.